A Population-Specific Ensemble Machine Learning Model for Predicting Borderline or Malignancy Risk of Ovarian Masses in Macao: A Multicenter Retrospective Study [0.03%]
澳门女性卵巢肿物上皮性肿瘤恶性的预测模型的建立及验证：一项多中心回顾性研究
Chan-Fong Chio,Lai-Fong Sin,Hoi-Sun Loi et al.
Chan-Fong Chio et al.
Background: Preoperative discrimination between benign and malignant ovarian tumors is important. The applicability of published prediction tools may be limited across different health systems. We aim to develop a machine...
A Clinicopathology and Simplified Molecular Marker-Based Risk Stratification Model for Predicting 3-Year Recurrence in Endometrial Cancer [0.03%]
子宫内膜癌复发的临床病理和简化分子标记风险分层模型及其3年预测价值
Juntao Zhang,Yichuan Zhou,Yuzhen Huang et al.
Juntao Zhang et al.
Background: The integration of clinicopathological parameters and molecular biomarkers holds significant prognostic value for endometrial carcinoma (EC) recurrence assessment. The purpose of this study is to combine clini...
First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort [0.03%]
越南人群一线 modified-FOLFIRINOX 治疗晚期胰腺癌的疗效及预后因素分析
Huy Van Nguyen,Phuong Thi Dinh,Thang Tran et al.
Huy Van Nguyen et al.
Background: Metastatic pancreatic cancer is an aggressive malignancy with limited survival despite intensive chemotherapy. While modified FOLFIRINOX (mFOLFIRINOX) has illustrated efficacy, its real-world data are limited ...
Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment [0.03%]
初次接受R-CHOP方案治疗的新诊断弥漫大B细胞淋巴瘤患者发生发热性中性粒细胞减少的风险因素分析
Liang-Ying Chen,Che-An Tsai,Po-Wei Liao et al.
Liang-Ying Chen et al.
Background: Febrile neutropenia (FN) frequently occurs as a complication among patients with diffuse large B-cell lymphoma (DLBCL) receiving their initial rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre...
National Patterns of Biomarker Testing in Colorectal, Lung, and Prostate Cancers: Insights From the NIH All of Us Research Program [0.03%]
美国国家癌症研究所全民计划中 colorectallung 和 prostate 癌症生物标志物检测的地域模式和人口统计学差异：来自 NIH“全民项目”的见解
Patrick J Kiel,Mark W McGiffin,Michael A Preston
Patrick J Kiel
Background: Biomarker testing is central to precision oncology, yet real-world implementation across cancer types and populations remains inconsistent. Social determinants of health (SDoH) may influence testing uptake and...
The Prognostic Significance of KRAS, NRAS, and BRAF Mutations in Colorectal Cancer: A Systematic Review and Meta-Analysis [0.03%]
KRAS、NRAS和BRAF突变在结直肠癌预后中的意义：系统性回顾及meta分析研究
Mathew Oyelami,Odinaka Mgbeke,Abraham Agaya Obadiah et al.
Mathew Oyelami et al.
Background: Colorectal cancer (CRC) remains a global health issue with high morbidity and mortality. According to molecular profiling, genetic mutations such as KRAS, NRAS, and BRAF play a significant role in tumor biolog...
Bevacizumab Plus EGFR-TKIs vs EGFR-TKIs Alone for Advanced EGFR-Mutant NSCLC: A Meta-Analysis [0.03%]
贝伐单抗联合表皮生长因子受体酪氨酸激酶抑制剂对比单纯表皮生长因子受体酪氨酸激酶抑制剂治疗晚期表皮生长因子受体突变型非小细胞肺癌： meta分析
Zexian Wang,Yaru Guo,Xiaohan Qin et al.
Zexian Wang et al.
Background: The goal of this comprehensive meta-analysis was to evaluate the efficacy and safety of combining Epidermal Growth Factor Receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with bevacizumab vs EGFR-TKI monother...
Clinical Analysis of Peripheral Blood Indicators for Immune-Related Adverse Events (irAEs) in Patients With Advanced Lung Cancer [0.03%]
晚期肺癌患者免疫相关不良事件(irAEs)外周血指标的临床分析
Yin-Min Ji,Yu-Hui Qin,Ya-Hui Lv et al.
Yin-Min Ji et al.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized advanced lung cancer treatment, but immune-related adverse events (irAEs) remain a significant challenge. This study aimed to identify peripheral blood i...
Effectiveness and Safety of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective Real-World Study in China [0.03%]
阿特朱单抗联合贝伐珠单抗治疗不可切除的肝细胞癌的有效性和安全性：中国多中心真实世界回顾性研究
Minghua Shao,Binbin Tan,Chao Fan et al.
Minghua Shao et al.
Background: Atezolizumab combined with bevacizumab (Atezo + Bev) has received regulatory approval as a first-line systemic therapy for unresectable hepatocellular carcinoma. This study aimed to evaluate the effectiveness ...
Development of Nomogram for Predicting Postoperative Progression Risk in High-Risk Thymoma and Thymic Carcinoma Utilizing Clinical and Preoperative CT Features [0.03%]
基于临床和术前CT特征的高危胸腺瘤及胸腺癌术后复发风险预测列线图的建立
Qian Meng,Nan Jiang,Jun Chen et al.
Qian Meng et al.
Background: Computed tomography (CT) features and clinical characteristics have been shown in recent studies to be effective predictive indicators for risk stratification of thymic epithelial tumors. High-risk thymoma and...